ABCG2 and neoplasm: In vivo, we found that the combination of topotecan with the well-tolerated Ko143, a dual inhibitor of ABCB1 and ABCG2, reduced tumor growth by more than 240% compared to single agents treatment, translating to an increase in survival from 17 to 28 days [46].